Business News

May 9thThe Drug Evaluation Center of the National Medical Products Administration indicates that HaixikeKligabaling (HSK16149) is to be included in priority review.used for neuropathic pain.

Source of image:National Medical Products Administration Drug Evaluation Center

Simecin ® (Clopidogrel Benzoate Capsules) was independently developed in China. It is the world's first third-generation calcium ion channel modulator that does not require titration. Utilizing an innovative tricyclic cage structure, it enhances molecular rigidity, offers high target selectivity and binding strength, while providing a larger safety margin. Treatment can be started with an effective dose, resulting in better pain relief and good overall tolerance.

Approved for market launch in May 2024, it has been approved in China for the treatment of diabetic peripheral neuropathy in adults (DPNP) and post-herpes zoster neuralgia (PHN).

It is the first class I new drug approved with a DPNP indication in mainland China, filling a treatment gap in this field. Its phase III study on central nervous system pain (cNP) is the first registered study to obtain a positive result in cNP in China.